Liège, Belgium, December 30, 2022 – 5.45 p.m. CET – In accordance with article 15 of the law of May 2, 2007 relating to the disclosure of significant holdings in issuers whose shares are
admitted to trading on a regulated market and containing various provisions, Mithra Pharmaceuticals SA (“the Company” or “Mithra”) publishes the following information, following
the issue of 262,000 new shares today for a total amount of EUR 1,165,900 following the put option notification issued on November 17, 2022 under the commitment agreement
of LDA Capital concluded in April 2020 and extended in April 2022.
As a reminder, LDA Capital commits cash funds of up to EUR 75 million for a maximum period of five years, in exchange for new Mithra shares. This is the fifth draw
linked to this agreement, leaving EUR 52,834,100 million available to Mithra.